IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 99.02

Change

-0.07 (-0.07)%

Market Cap

N/A

Volume

0.12M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.26 (-0.17%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.02 (-0.03%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.02 (-0.02%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.11 (-0.12%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.09 (-0.38%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.40 (+1.07%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.43 (+0.44%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.19 (-0.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.22 (+0.76%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.88 % 0.00 %

-1.96 (-1.33%)

USD 1.47B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

-0.15 (-1.33%)

CAD 0.65B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.18% 76% C+ 72% C
Dividend Return 0.78% 80% B- 18% F
Total Return 14.96% 76% C+ 68% D+
Trailing 12 Months  
Capital Gain 17.23% 48% F 62% D
Dividend Return 1.45% 94% A 22% F
Total Return 18.68% 52% F 57% F
Trailing 5 Years  
Capital Gain 59.63% 71% C- 76% C+
Dividend Return 6.18% 72% C 19% F
Total Return 65.82% 71% C- 74% C
Average Annual (5 Year Horizon)  
Capital Gain 7.46% 67% D+ 63% D
Dividend Return 8.42% 67% D+ 58% F
Total Return 0.96% 74% C 21% F
Risk Return Profile  
Volatility (Standard Deviation) 10.68% 95% A 76% C+
Risk Adjusted Return 78.76% 81% B- 90% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike